A Prospective, Single-Arm, Phase II Clinical Study of Nimotuzumab Combined With Radiotherapy for Elderly Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

This is a prospective, single-center, open-label, single-arm phase II study. The purpose of this study is to evaluate the efficacy and safety of nimotuzumab combined with concurrent intensity-modulated radiotherapy (IMRT) in elderly patients (≥65 years old) with locally advanced unresectable head-and-neck squamous cell carcinoma (HNSCC) who are unfit for standard concurrent cisplatin-based chemoradiotherapy. Eligible patients will receive standard-dose intensity-modulated radiotherapy together with weekly nimotuzumab. The primary endpoint is 1-year overall survival rate. Secondary endpoints include progression-free survival, objective tumor response rate, locoregional control rate, distant metastasis rate, and treatment-related adverse events. Patients will be followed up for survival, tumor status and safety assessments after treatment completion.

Start Date10 Sep 2026

Sponsor / Collaborator

Peking Union Medical College Hospital

NCT07736612

/ Not yet recruitingPhase 1/2IIT

A Phase Ib/II Study of the Safety, Tolerability, and Efficacy of a Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.

Start Date15 Aug 2026

Sponsor / Collaborator

Zhejiang University

ChiCTR2600128718

/ SuspendedPhase 2IIT

A Prospective, Single-Arm, Phase II Clinical Study of Nimotuzumab Combined with Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Resectable Oral Squamous Cell Carcinoma

Start Date01 Aug 2026

Sponsor / Collaborator

The First Affiliated Hospital, Zhejiang University Sch of Med

100 Clinical Results associated with Nimotuzumab

100 Translational Medicine associated with Nimotuzumab

100 Patents (Medical) associated with Nimotuzumab

380

Literatures (Medical) associated with Nimotuzumab

01 Nov 2026·INTERNATIONAL JOURNAL OF CANCER

Nimotuzumab Combined With Concurrent Curative Radiotherapy and S‐1 in 75 Years and Older Patients With Stage II ‐ IVB Esophageal Squamous Cell Carcinoma: A Phase II Study

Article

Author: Ge, Xiaolin ; Sun, Xinchen ; Chen, Hui ; Xia, Xiaojie ; Xu, Lu ; Yan, Jingze

ABSTRACT:

Concurrent chemoradiotherapy is the standard treatment for inoperable, locally advanced esophageal cancer. However, older patients often have reduced tolerance to radiotherapy and concurrent intravenous chemotherapy due to declining physical function and multiple comorbidities. This prospective, single‐center, phase II study assessed the efficacy and safety of nimotuzumab, an epidermal growth factor receptor antagonist, combined with concurrent radiotherapy and S‐1 in patients 75 years and older. A total of 56 patients were enrolled, with the primary endpoint being progression‐free survival (PFS), while secondary endpoints included overall survival (OS), objective response rate, disease control rate, treatment‐related adverse events, nutritional indicators, and quality of life (QOL). Most nutritional indicators remained stable after treatment. As of June 2024, the median follow‐up duration was 24.1 months (8.8–34.1). Eleven patients achieved complete response, 39 achieved partial response, five had stable disease, and one experienced progressive disease. The median PFS was 25.3 months (95% CI, 16.5–34.1), while the median OS was 28.2 months (95% CI, 24.1–32.3). Most adverse events were grade 1–2 (85.7%). Among survivors, 45.5% reported high satisfaction with their QOL, and 84.8% did not experience weight loss. This combination therapy demonstrated promising efficacy and safety, suggesting it may be a viable treatment option for this patient population.

01 Oct 2026·Clinical Pharmacology in Drug Development

A Phase I Study of Nimotuzumab Combined with Irinotecan in Chinese Patients with Advanced Solid Tumors

Article

Author: Jiang, Zhichao ; Du, Chunxia ; Sun, Yongkun ; Zhou, Aiping ; Zhang, Wen

Abstract:

Nimotuzumab is an anti‐epidermal growth factor receptor antibody. This Phase I study evaluated the pharmacokinetics and safety of nimotuzumab plus irinotecan in Chinese patients with advanced solid tumors. At single ascending dosage (SAD) stage, four cohorts (100, 200, 400, and 600 mg) of patients received nimotuzumab intravenously on Day 1, alongside irinotecan 180 mg/m 2 on Day 8. Three weeks later, all patients in the four cohorts transferred to multiple ascending dosage (MAD) stage: nimotuzumab was administrated weekly for 6 weeks, alongside irinotecan (Days 1, 15, 29, 43, and 57, 180 mg/m 2 ). Primary objective was pharmacokinetics, safety and tolerability was also examined. From December 2012 to October 2014, in SAD and MAD stages, there were 28 and 39 patients with Stage IV solid tumors. The area under the concentration curve (AUC 0–∞ ) for a single dose of nimotuzumab was 10.2 ± 2.7 (100 mg), 37.6 ± 10.0 (200 mg), 114.8 ± 35.5 (400 mg), 197.6 ± 32.0 (600 mg) (×100 h µg/mL), and for multiple dose, it was 26.7 ± 3.4 (100 mg), 87.1 ± 12.0 (200 mg), 193.4 ± 46.9 (400 mg) and 446.3 ± 100.7 (600 mg) (×100 h µg/mL). There was low incidence of rash and no dose‐limiting toxicities occurred. This study indicated that nimotuzumab at doses ranging from 100 to 600 mg exhibited a manageable and tolerable safety profile.

01 Sep 2026·EClinicalMedicine

Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial

Article

Author: Wang, Lin ; He, Shuiqing ; Tang, Linquan ; Chen, Chunyan ; Ye, Yanfang ; Bei, Wei-Xin ; Zhao, Ze-Yu ; Lv, Shuhui ; Lu, Nian ; Xiang, Yan-Qun ; Liu, Liting

Background:

Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) who progress after immune checkpoint inhibitor (ICI) therapy have limited treatment options and poor outcomes. We evaluated the efficacy and safety of liposomal irinotecan plus nimotuzumab in patients with epidermal growth factor receptor (EGFR)-positive, ICI-refractory R/M NPC.

Methods:

In this single-arm, open-label, phase II trial (NCT06414577) conducted in China, patients with EGFR-positive, ICI-refractory R/M NPC were enrolled between May 27, 2024, and January 9, 2025. Patients received intravenous liposomal irinotecan (70 mg/m²) plus nimotuzumab (400 mg) every 2 weeks for up to eight cycles. The primary endpoint was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1.

Findings:

Thirty-six heavily pretreated patients were enrolled, of whom 12 (33.3%) had received three or more prior lines of therapy for advanced disease. In the intention-to-treat population, 13 of 36 patients achieved an objective response (ORR 36.1%; 95% CI 20.8-53.8), and 22 of 36 patients achieved disease control (61.1%). Median progression-free survival was 3.0 months (95% CI, 2.2-4.1), and median duration of response was 2.3 months (95% CI 1.5-3.1). After a median follow-up of 22.0 months, the median overall survival was 14.1 months (95% CI, 8.7-not estimable). Grade 3 or higher treatment-related adverse events occurred in eight of 36 patients (22.2%), and no treatment-related deaths were observed. In a post-hoc exploratory analysis, an early decline of at least 50% in plasma Epstein-Barr virus DNA was associated with a higher ORR.

Interpretation:

Liposomal irinotecan plus nimotuzumab showed preliminary antitumor activity and manageable safety in heavily pretreated patients with ICI-refractory R/M NPC. However, response durability was limited, and further comparative studies are needed to evaluate its clinical value and identify patients most likely to derive durable benefit.

Funding:

Supported by grants from the National Natural Science Foundation of China, Science and Technology Program of Guangdong Esophageal Cancer Institute, and China Postdoctoral Science Foundation.

News (Medical) associated with Nimotuzumab

14 Sep 2022

·www.globenewswire.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent is expected to expire no earlier than February 2039. The allowed claims cover a method of treating a patient diagnosed with glioblastoma or recurrent glioblastoma, wherein the patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents including temozolomide (TMZ), carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), and recombinant oncolytic poliovirus (PVS-RIPO). The allowed claims cover a wide range of doses of MN-166 (ibudilast) as well as the other therapeutic agents. The allowed claims also cover different types of glioblastoma including classical glioblastoma, proneural glioblastoma, mesenchymal glioblastoma, and neural glioblastoma. Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc. commented, “We are very pleased to receive the issue notification for this new patent as it offers additional coverage compared to our other two patents covering glioblastoma. We have an ongoing clinical trial of MN-166 in combination with temozolomide for the treatment of recurrent glioblastoma at the Dana-Farber Cancer Institute, Harvard Medical School. Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone, and this data was presented at the American Society of Clinical Oncology (ASCO) annual meeting. Encouragingly, the FDA granted orphan-drug designation to MN-166 as adjunctive therapy to temozolomide for the treatment of glioblastoma based on this data.” About Glioblastoma According to the American Association of Neurological Surgeons, glioblastoma is an aggressive brain cancer that often results in death during the first 15 months after diagnosis. Glioblastoma develops from glial cells (astrocytes and oligodendrocytes), grows rapidly, and commonly spreads into nearby brain tissue. Glioblastoma is classified as Grade IV, the highest grade, in the World Health Organization (WHO) brain tumor grading system. The American Brain Tumor Association reports that glioblastoma represents about 15% of all primary brain tumors and approximately 10,000 cases of glioblastoma are diagnosed each year in the U.S. Despite decades of advancements in neuroimaging, neurosurgery, chemotherapy and radiation therapy, only modest improvements have been achieved and the prognosis has not improved for individuals diagnosed with glioblastoma. Median survival is about 11-15 months for adults with more aggressive glioblastoma (IDH-wildtype) who receive standard treatment of surgery, temozolomide, and radiation therapy. About MN-166 (ibudilast) MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2021 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT:Geoff O'BrienVice PresidentMediciNova, Inc.info@medicinova.com

Radiation TherapySmall molecular drugASCOCollaborateIPO

25 Sep 2019

·www.biospace.com

Biocon Biologics Expands its R&D Footprint Through Acquisition

60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists 60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists Bengaluru, Karnataka, India: September 24, 2019: Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, today announced that its subsidiary, Biocon Biologics , has acquired R&D capital assets for a 60,000 sq. ft state-of-the-art ‘bench to pilot scale’ Biologics research facility at TICEL Bio Park in Chennai, India. Biocon Biologics has acquired these assets from Pfizer Healthcare India Ltd. Dr Christiane Hamacher, CEO, Biocon Biologics, said: “The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide. This investment will allow us to fast-forward development of our biosimilars from lab to pilot scale. R&D is at the core of what we do and I believe this facility will enable us to pursue breakthrough innovation in pursuit of providing affordable access to high quality biosimilars and inclusive healthcare solutions aimed at transforming patient lives globally.” The facility will house an early stage research and innovation center including a pilot scale R&D Unit, well-equipped with cell line development, drug substance process development from bench scale to 400 litre scale bioreactors, drug product formulation laboratories and analytical R&D laboratories. The facility is expected to be operational in a few months post qualification and will house over 250 scientists who will have access to state of the art R&D labs equipped with over 500 high- end process and analytical instrumentation. The new facility provides Biocon Biologics a significant time advantage in comparison to setting up a greenfield R&D project and will accelerate the global development of our biosimilars portfolio. Currently, Biocon Biologics has a 200,000 sq. ft state of the art Research & Development Centre at Biocon Park, Bengaluru, India. The Company has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own. The financial details of the deal are confidential. TICEL Bio Park at Chennai, Tamil Nadu, India, is a hub for the biotech R&D industry in major domains such as medical biotechnology, nutraceuticals, agricultural biotechnology and bioinformatics and provides world class infrastructure support. About Biocon Biologics Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company. Biocon Biologics is engaged in developing high quality, affordable biosimilars that can expand access to a cutting-edge class of therapies to patients globally. It is uniquely positioned as the fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in the developed markets of EU, U.S. and Japan. It has obtained approvals and commercialized a range of biosimilars, including monoclonal antibodies for cancer, Pegfilgrastim, rh-Insulin and Insulin Glargine on its own or through partners in key global markets. Biocon Biologics believes that strong partnerships offer enormous opportunities to co-create the future of healthcare, building a patient ecosystem beyond the product, which can transform millions of lives. About Biocon Ltd: Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is a fully-integrated, innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. The Company has developed and commercialized a range of Biosimilars (Monoclonal Antibodies, Pegfilgrastim, rh- Insulin and Insulin Glargine), Novel Biologics and differentiated Small Molecules in India and key emerging markets. It has a large portfolio of biosimilars and promising novel assets in immunotherapy under global development. Some of its key formulations brands are INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab). Follow-us on Twitter: @bioconlimited FOR MORE INFORMATION MEDIA RELATIONS Seema Ahuja Sr. VP & Global Head, Corporate Communications (+91 80 2808 2222 ( +91 99723 17792 * seema.ahuja@biocon.com INVESTOR RELATIONS Saurabh Paliwal Head, Investor Relations ( +91 80 6775 2040 ( +91 95383 80801 * investor.relations@biocon.com DISCLAIMER : This press release may include statements of future expectations and other forward-looking statements based on management’s current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

ImmunotherapyDrug ApprovalAcquisition

25 Apr 2014

·www.daiichisankyo.com

Daiichi Sankyo Announces Discontinuation of Phase 3 Clinical Trial in Japan of Nimotuzumab (DE-766) in Lung Cancer

PDF (61KB)PDF For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Corporate Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 http://www.daiichisankyo.com/ TOKYO, Japan (April 25, 2014) - Daiichi Sankyo Company, Limited announced today the discontinuation of the phase 3 clinical trial conducted in Japan for nimotuzumab (DE-766) in Lung Cancer. The phase 3 clinical trial was a multicenter, randomized, double-blind, placebo-controlled study investigating nimotuzumab for first-line therapy in patients with unresectable and locally advanced squamous cell lung cancer. Patients received either nimotuzumab in combination with concurrent chemoradiotherapy or a placebo in combination with concurrent chemoradiotherapy. The study was discontinued based on the recent recommendation of the Independent Data Monitoring Committee which observed safety issues in certain patients who received a combination of cisplatin, vinorelbine, radiotherapy, and nimotuzumab. About Unresectable and Locally Advanced Squamous Cell Lung Cancer In Japan, lung cancer is the first leading cause of cancer death with about 70,000 deaths in 2011.i Non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) occupies more than 80 percent of lung cancer. Concurrent chemoradiotherapy for a radical cure is currently used as the standard treatment for patients with stage III locally advanced non-small cell lung cancer, in which radical surgery is not possible but radiotherapy is.ii Of these cases, between 30 and 40 percent are squamous cell carcinoma and EGFR is known to be overexpressed.iii About Nimotuzumab and EGFR Nimotuzumab is an intravenously administered recombinant humanized monoclonal antibody directed against human Epidermal Growth Factor Receptor (EGFR) and is produced by CIMAB S.A. (Cuba). nimotuzumab blocks the binding of Epidermal Growth Factor (EGF) to its receptor interfering with the cell signaling pathway. Nimotuzumab has been approved for head and neck cancer, glioma, and esophageal cancer in several countries and used in 29 completed and 26 on-going trials worldwide without any major safety concern so far. EGFR is known to be overexpressed in a wide variety of human tumors.iv Overexpression of EGFR in tumors correlates with increased metastasis, decreased survival, and a poor prognosis. It is known that EGFR is activated by exposure to radiation. In 2006, Daiichi Sankyo introduced nimotuzumab from CIMAB S.A. and CIMYM BioSciences Inc. (Canada) and has the rights to develop and commercialize in Japan. Reference i) Vital Statistics of Japan (Ministry of Health, Labour and Welfare); 2011. ii) Lung Cancer Clinical Practice Guidelines (Japan Lung Cancer Society); 2012. iii) Ito T, Ishii G, Nagai K, et al. Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer 2009; 63(3):418–424. iv) Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.

Phase 3Drug Approval

100 Deals associated with Nimotuzumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nimotuzumab	L04AG L01XC	DB06192

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pancreatic Cancer	China	Biotech Pharmaceutical Co., Ltd.	07 Jun 2023
Squamous Cell Carcinoma of Head and Neck	Indonesia	Innogene Kalbiotech Pte Ltd.	19 Oct 2022
Nasopharyngeal Carcinoma	China	Biotech Pharmaceuticals Pty Ltd	07 Jan 2008
Glioma	Ukraine	Oncoscience AG	10 Oct 2007
Head and Neck Neoplasms	India	Biocon Biopharmaceuticals Pvt Ltd.	11 Sep 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal junction adenocarcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Aug 2024
Gastrooesophageal junction cancer	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Aug 2024
stomach adenocarcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Aug 2024
Metastatic Colorectal Carcinoma	Phase 3	-	Biotech Pharmaceutical Co., Ltd.	03 Apr 2024
Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Nov 2021
Diffuse Intrinsic Pontine Glioma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	03 Apr 2021
Cervical Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	10 May 2016
Esophageal Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	13 Nov 2015
Metastatic Esophageal Squamous Cell Carcinoma	Phase 3	China	Biotech Pharmaceutical Co., Ltd.	01 Nov 2015
Uterine Cervical Cancer	Phase 3	Algeria	-	28 Oct 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06389760 (ESMO2026)	Phase 2	Pancreatic Cancer Adjuvant	52	Nimotuzumab plus mFOLFIRINOX	yairxlcsmi(tvyomxhprc) = xfntacpcnz tmaymxnduj (oypqyjevzq ) View more	Positive	23 Oct 2026
				Nimotuzumab plus gemcitabine+capecitabine	oguvkbewjo(rbsjjwuxwy) = wwgebpaeal qdeqobawzr (syiuvhbege )
ESMO2026	Phase 2	Esophageal Carcinoma	60	Radiotherapy+S-1+nimotuzumab	tspmkbvtnb(wqayjawpjt) = grczquikks qonheyizqz (rhixlrvuhd, 69 - 89) View more	Positive	23 Oct 2026
EANO2026	Not Applicable	-	12	Radiotherapy + Nimotuzumab/Vinorelbine regimen (NV)	dvgvtzetxb(bxcvoreefv) = wbpedpgwro hgrkgdpsxk (yysvixvqoy, 0 - 43) View more	Negative	24 Sep 2026
NCT03766178 (Pubmed \| J Immunother Cancer)	Phase 2	Advanced Esophageal Squamous Cell Carcinoma Second line EGFR amplification \| MUC16 mutations \| NOTCH3 mutations ... View more	46	Camrelizumab 200 mg + nimotuzumab 400 mg	qiuxbncvli(mesrzydfyo) = cnjhiayfdy wofylovjss (xwvwvjcbpq, 19.5 - 48.0) View more	Positive	01 Sep 2026
				Camrelizumab 200 mg + nimotuzumab 400 mg	qiuxbncvli(mesrzydfyo) = etxikdvayk wofylovjss (xwvwvjcbpq )
NCT07353723 (Pubmed \| Front Immunol)	Phase 2	Tonsillar Neoplasms Neoadjuvant	20	Nimotuzumab + Toripalimab + Nab-paclitaxel + Carboplatin	doufptqfkp(kbejnxdmzu) = bczceuibwc jrgodeadix (rblmlmnsft ) View more	Positive	14 Jul 2026
NCT05717790 (ASCO_Breakthrough2026)	Phase 3	Advanced Nasopharyngeal Carcinoma	172	Nimotuzumab plus standard therapy (Stage III-IVa nasopharyngeal carcinoma)	obadsjhagm(rursdmqvja) = vsbvhdxeai efzmlfyuzk (oijhgufmpb ) View more	Positive	25 Jun 2026
				Standard therapy (Stage III-IVa nasopharyngeal carcinoma)	obadsjhagm(rursdmqvja) = zoxelydjjx efzmlfyuzk (oijhgufmpb ) View more
ASCO_Breakthrough2026	Not Applicable	Head and Neck Neoplasms	108	Concurrent chemoradiotherapy (inj. cisplatin 30 mg/m2 weekly)	xkzhgqrymw(aftuyhvbdt) = Toxicity was grade 2 and 3 in both group some patient only grade 4 toxicity in both arm xllrlhgago (xvcjbpdfol )	Positive	25 Jun 2026
				Concurrent chemoradiotherapy (inj. cisplatin 30 mg/m2 weekly) + Inj nimotuzumab 200mg/weekly
NCT04475016 (ASCO_Breakthrough2026)	Phase 2	Squamous Cell Carcinoma of the Penis Neoadjuvant	29	Toripalimab plus nimotuzumab combined with taxol-based chemotherapy (TNT regimen)	pcralsunnw(eikopkoqab) = mrnroknrvc ivudvythof (hoecqcwmvu, 54.1 - 88.2) View more	Positive	25 Jun 2026
				Toripalimab plus nimotuzumab combined with taxol-based chemotherapy (TNT regimen) (non-pCR group)	bdsukuxmil(tlrgpoxmdm) = usroacyauo edirehyitb (arakkndetz, 12 - NR) View more
NCT06879691 (ASCO2026)	Phase 3	Head and Neck Neoplasms	194	nimotuzumab + analgesics + CCRT	iurpreuncu(ipktdfyamo) = upxvgzrwmz xbnrogkmbi (erffijpqai ) View more	Positive	29 May 2026
				analgesics + CCRT	iurpreuncu(ipktdfyamo) = dnniujcwmt xbnrogkmbi (erffijpqai ) View more
ASCO2026	Not Applicable	Metastatic Esophageal Squamous Cell Carcinoma First line EGFR gene amplification	497	Nimotuzumab + Paclitaxel + Cisplatin	juileugmlk(txpwcmfykj) = mycolcbazg xretrahxcf (wdtokabpao ) View more	Positive	29 May 2026
				Placebo + Paclitaxel + Cisplatin	juileugmlk(txpwcmfykj) = uljthndzqb xretrahxcf (wdtokabpao ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis